The Latest Breaking News from ABBV

After Humira’s patent cliff, what do analysts think about AbbVie’s stock now?

These three dividend stocks are long-term winners with dependable payouts.

3 top-performing Dividend Kings of 2025 based on their Year-to-Date percent change.

An intriguing quant signal combined with shifting sentiment in the derivatives market opens the possibility toward a bullish trade for ABBV stock.

AbbVie, McDonald’s, and Walmart offer growth, rising dividends, and valuation upside as investors seek blue-chip stability heading into 2026

AbbVie has outperformed the Nasdaq over the past year, and analysts are moderately optimistic about the stock’s prospects.

Win through diversification: mix stable, income-generating Dividend Aristocrats for growth, reliability, and long-term returns.

Traders are increasingly turning to zero-days-to-expiration (0DTE) options to target fast-moving market reactions, including earnings announcements. The high leverage and compressed timeframe offered by these setups can deliver outsized returns, but those same dynamics leave little margin for error when it comes to timing and execution.

Although AbbVie has underperformed the S&P 500 Index over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.